The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Alison Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Charlene Mantia
Consulting or Advisory Role - AADi; Nextech; Synthekine
Research Funding - Bristol-Myers Squibb (Inst)
 
Evan Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Oncternal Therapeutics (Inst); Seagen (Inst); Tyra Biosciences (Inst)
 
Andrew Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Merck Sharp & Dohme
 
Marie Robert
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Rafael Morales-Barrera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck/Pfizer; MSD; Sanofi
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Merck; MSD; Pfizer; Roche/Genentech; Sanofi
 
Christopher Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Amgen (Inst); Bristol-Myers Squibb; crispr therapeutics (Inst); Eisai; Genentech/Roche; Merck Sharp & Dohme; NeoImmuneTech (Inst); Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Jordan Berlin
Consulting or Advisory Role - amplia; Astellas Pharma; Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; epsilon; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; BeiGene; IQvia; Lilly; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
Christine Lihou
Employment - Tyra Biosciences
Stock and Other Ownership Interests - Tyra Biosciences
Research Funding - Tyra Biosciences
 
Yohan Loriot
Honoraria - Astellas Amgen BioPharama; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Seattle Genetics/Astellas; Taiho Oncology
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Seattle Genetics/Astellas; Taiho Oncology
Research Funding - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Celsius Institution; Exelixis; Gilead Sciences; Incyte; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Seattle Genetics/Astellas; Taiho Oncology
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme; Pfizer
 
Damien Pouessel
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer/Astellas
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Eisai; Merck; MSD Oncology; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Kriti Mittal
Honoraria - Aptitude Health; Cardinal Health; IntrinsiQ; Medpage; Research to Practice; Research to Practice; Targeted Oncology; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Aveo; AVEO; Curio Science; Dendreon; Janssen; Myovant Sciences
Research Funding - Pfizer
 
Andrew Hill
Employment - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
 
Fabricio Racca
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma